Cagrilintide
Regulatory registry
- Context
- Investigational / no FDA-approved-treatment claim
- Reason / limits
- FDA says cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.
- Last source review
- October 15, 2026
- Review scope
- FDA regulatory source rechecked October 15, 2026. Trial context retains its earlier review date.
- Clinical phase
- Unknown: no current trial-specific phase check is included in this registry.
- Registry NDC / manufacturer
- Unknown unless linked to a matched FDA package record below.
Research-only means this library makes no approved-treatment claim. Compounding context does not mean compounded-only, authorized for compounding, or legally available. Product-specific source limits control.
Regulatory sources
FDA shortage tracker
Approval context and shortage status are separate. An NDC identifies a package; it does not establish FDA approval or permission to compound.
UnknownUnknown: no exact single-substance FDA shortage record matched. Absence from the dataset is not proof of availability or approval.
Full dated shortage record · All compound tracker entries
Matched package records (0)
Records match a single exact active substance. Route and presentation are shown separately; a record does not apply to every product or preparation.
No exact matched package records. NDC and manufacturer: Unknown. No stock claim is made.
Observed change history (0)
Observed dates are when our sync saw a source state, not when a shortage started or ended. Unchanged daily checks do not add duplicate events.
No observed status changes yet.